Reply to editorial comment

This is the first study about the technical feasibility of endoscopic robotic-assisted simple enucleation (ERASE) of renal cell carcinoma. In our opinion, the primary advantage of ERASE is the combination of the benefits of the simple enucleation (SE), namely the maximum preservation of renal parenchyma, a proven oncologic safety and a low rate of calyceal tearing or vascular injuries that can minimize the risk of Clavien III complications,1 with the advantages of mini-invasivity, such asinstruments must always be under strict and continuous visual control, transmitting the pressure over a large surface of the tumor with the back of the monopolar scissors and bipolar Maryland forceps. Finally, the postoperative surgical complications were lower in the ERASE group than in the OSE group (8.8% vs 13.8%). The lack of statistical significance may have been caused by the low number of events in the 2 matched groups. We cannot exclude that increasing the numbers would allow this difference to achieve the statistical significance. In conclusion, this study represents the first analysis of SE done with the robotic system. ERASE will require further investigation, ideally multi-institutional, to assess the oncologic efficacy and the reproducibility of this technique, as recently has occurred for OSE.3 Andrea Minervini, M.D., Ph.D., Gianni Vittori, M.D., Marco Carini, M.D., and Sergio Serni, M.D., Ph.D., Department of Urology, University of Florence, Careggi Hospital, Florence, Italy